Untreated HIV-1 infection progresses through acute and asymptomatic stages to AIDS. Although each of the three stages has well-known clinical, virologic, and immunologic characteristics, much less is known of the molecular mechanisms underlying each stage. In this study, we report lymphatic tissue microarray analyses, revealing for the first time stage-specific patterns of gene expression during HIV-1 infection. We show that although there is a common set of key genes with altered expression throughout all stages, each stage has a unique gene expression signature. The acute stage is most notably characterized by increased expression of hundreds of genes involved in immune activation, innate immune defenses (e.g., RIG-1, MDA-5, TLR7 and TLR8, PKR, APOBEC3B, 3F, 3G), adaptive immunity, and in the proapoptotic Fas-Fas ligand pathway.
granzymes and killer-specific secretory protein of 37 kDa increased, consistent with innate and adaptive defenses by NK cells and CTL.
Apoptosis accounted for ~4% (14 genes) of unique acute stage genes. Quite selectively, among numerous canonical apoptotic pathways, only the Fas-Fas ligand-mediated cell death pathway was activated (Fig. 3) . Proapoptotic genes increased in this pathway included Fas ligand, caspases 3 and 4, BH3-interacting domain death agonist (BID), and truncated BID, highlighting the importance of the Fas-Fas ligand pathway in LT during acute stage infection.
Finally, tissue repair/remodeling and metabolism accounted for, respectively, ~9% (33 genes) and ~24% (87 genes) of unique acute stage genes. Notable are chitinase 3 like-2, decorin, and dermatopontin, genes that could be plausibly involved in collagen formation/ deposition, an important pathologic process observed in HIV-1 infection (8). Also, ~90% (78 genes) of metabolism genes were increased in expression, suggesting accelerated cell growth and turnover.
Asymptomatic stage
In contrast to the acute stage, the asymptomatic stage (region S2) had relatively few altered genes (18 genes; Fig. 2C ), reflecting a return to baseline levels of nearly all acute stage genes and a major shift in host response to the virus. We return in the Discussion to the mechanisms and significance of this striking change.
AIDS stage
Unlike the predominance of increased expression in the acute stage, genes unique to the AIDS stage (region S3) were largely decreased, ~84% of 183 (Fig. 2D ). These included genes involved in immune activation, apoptosis, and tissue repair/remodeling. Interestingly, a substantial number of decreased genes were involved in the CD28 T cell costimulatory pathway, key molecules such as CD28, Txk (Tec family of nonreceptor tyrosine kinases), the lymphocyte-specific serine/threonine kinase death-associated protein-related apoptotic kinase 2 (DRAK2/STK17b), and the Ca 2+ -binding protein calmodulin, suggesting, in addition to significant T cell loss, T cell stimulation may be compromised during AIDS.
The small number of AIDS stage genes increased in expression included the antiviral chemokine MIP-1α, the innate antimicrobial molecule S100A9, the DCl and monocytederived macrophage differentiation marker decysin, and the cell surface proteoglycan syndecan-1.
Discussion
The major finding of this study is that there are stage-specific transcriptional signatures in LTs during HIV-1 infection. These signatures identify constellations of gene expression relevant to understanding the molecular mechanisms involved in the pathogenesis of each stage.
In the acute stage of infection, the large number of altered genes, most of them increased in expression (~81%), provides a signature consistent with the dramatic pace and magnitude of events in this stage seen clinically, virologically, and immunologically. Although the explosive replication of virus to peak levels in the first month of infection is known to elicit immune activation and host defenses that partially control infection, the transcriptional signatures now provide a comprehensive picture of the genes in LTs involved in immune activation, partial control of infection, and moderation of the pathologic consequences of immune activation.
Another general feature of this acute stage transcriptional signature is that it is a mirror image (opposite) of the transcriptional signature of infected individuals' treated with highly active anti-retroviral therapy. In response to treatment and the control of viral replication, genes related to immune activation and innate/adaptive defenses decreased, in contrast to the increased expression in untreated acute infection shown here (i.e., immune defense genes such as IFN-γ, OAS, MX2, IDO, RIG-1, granzymes and immune activation genes such as STAT1, FGL2). This result supports a model proposed by Li et al. (7) , namely, that suppression of viral replication via treatment would relieve the stimulus driving gene expression regulating immune activation and defenses that were partially controlling infection, thus leading to decreased expression of these genes. The acute stage signature now confirms that prediction.
Not surprisingly, the host rapidly responds to HIV-1 infection by increasing expression of a large number of genes related to innate and adaptive defenses during the acute stage, such as IFN-related genes and those associated with NK cell-and CD8 + T cell-mediated cytotoxicity (Fig. 2B) . However, what was surprising was the breadth and distinctive nature of this response and its restriction to acute stage infection. For example, APOBEC3B, -3F, and -3G were only increased during this stage. The potent anti-HIV-1 properties via cytidine deamination-dependent (9) and -independent mechanisms (10) of APOBEC3F and -3G have been well documented, but APOBEC3B, previously considered an intrinsic cellular defense against endogenous retrotransposons (11), has only recently been shown to have anti-HIV-1 activity in vitro (12, 13). The transcriptional signatures now document in vivo deployment of three of the APOBEC proteins as a first line of defense against HIV-1.
A number of key pathogen recognition receptors also were increased in expression only during acute stage infection, e.g., RIG-I, MDA-5, PKR, and TLRs 7 and 8. These proteins work in concert to detect and inhibit invading pathogens by recognizing various forms of viral RNA, transducing a downstream signal that activates accessory proteins such as NF-κB and IFN regulatory factor 3, leading to the production of proinflammatory cytokines and type I IFN (14, 15). In addition to the production of type I IFNs, engagement of TLR7, which is highly expressed in plasmacytoid DCs (16), can enhance HIV-1-specific T cell responses (17) while TLR8 signaling can inhibit HIV-1 replication in susceptible target cells (18). The restricted up-regulation of TLRs 7 and 8 in acute stage infection is consistent with their importance in early detection of viral infection and the concept of robust expression of sentinel-like molecules to create an antiviral state in the initial stages of HIV-1 infection.
Not surprisingly as well, the largest number of altered genes during acute infection were related to immune activation, encompassing categories from cell cycle to proinflammatory mediators to genes involved in the proliferation of cells. However, what the acute stage signature surprisingly reveals is the distinctive nature of genes in LTs involved in immune activation and their restriction to this stage. For example, among all of the potential proinflammatory cytokines, we only observed increased expression of the gene encoding cytokine IL-32.
IL-32 is an inflammatory cytokine induced by T H 1-type cytokines in various cell types (19, 20) and has only recently received increased attention as an important component in autoimmune and inflammatory diseases through induction of other proinflammatory cytokines such as TNF-α (19-21), IL-1β (20, 21), IL-8 (19), and MIP-2 (19, 21). Additionally, one report (22) has implicated IL-32 in activation-induced cell death in T cells. This is the first study showing IL-32 expression in LTs in HIV-1 infection. IL-32 likely contributes to the exacerbation of inflammation during HIV-1 infection and may have an important, albeit heretofore unappreciated role in T cell death.
Interestingly, a number of pattern recognition receptors recognizing microbial products were also up-regulated during acute infection. Recent evidence has implicated microbial translocation from the gastrointestinal tract during HIV-1 infection as a factor driving systemic immune activation (23). The up-regulation of genes such as dectin-1 and galectin-3 may be key switches utilized by the host to recognize and alert the immune system to deal with an increase in foreign microbial products. Dectin-1 plays a key role in recognizing β-glucan-containing microorganisms and, once engaged, leads to the production of IL-23, a key cytokine involved in the generation of anti-bacterial Th17 cells (24). Galectin-3 has recently been shown to be a negative regulator of LPS-induced inflammation (25). The upregulation of these genes during acute infection suggests that the host may be responding to an increased presence of bacteria, a compensatory mechanism to curtail aberrant immune activation.
Among several apoptotic pathways, the acute stage signature strongly points to a principal role for Fas-Fas ligand-mediated apoptosis in LTs of HIV-1-infected subjects during this stage. Key apoptosis-related genes map strictly to the Fas-Fas ligand pathway, including downstream effectors such as BID, truncated BID, and caspase 3, all increased in expression (Fig. 3 ).
In the asymptomatic stage, the rapid return to levels of gene expression indistinguishable from uninfected HIV-1 uninfected subjects and the paucity of altered genes unique to this stage, 18 genes vs 358 unique acute stage genes, is remarkable, given evidence of ongoing viral replication and lymphoid tissue damage during this stage despite its relative clinical quiescence (6, 26) . This transition begins in the acute stage with increased expression of numerous immunosuppressive genes such as CLEC12B, ILT4, galectin-3, CD160, BCMA, FGL2, LAG3, GPNMB, and IDO at a time of immune activation, consistent with a role in moderating the immunopathological consequences of sustained immune activation and thereby contributing to slow disease progression characteristic of HIV-1, SIV, and other lentiviral infections. However, these moderating effects may come at a price, in dampening the immune response to infection and, in the long term, contributing to a dysfunctional and increasingly "exhausted" immune system (27).
The defining feature of the AIDS stage signature was decreased expression of most (~84%) of the 183 unique genes. Although decreased expression could be due to loss of cells expressing these genes, decreased expression in a particular cell type, or both, the net effect is the same dysfunctional host defenses due to decreased expression of various genes, such as: 1) CD244/2B4, a cell surface molecule expressed on NK and memory CD8 + T cells that determines the level of activation or inhibition based on the degree of receptor expression and extent of its ligation (28); 2) CCR7, the principal chemokine receptor responsible for migration of naive and memory T cells and DCs into lymph nodes (29); and 3) a number of genes involved in T cell activation/costimulation, most prominently the costimulatory signal-transmitting receptor CD28 (30) and other molecules associated with this pathway such as the T cell-specific tyrosine kinase Txk (31), DRAK2/STK17b, a serine/threonine kinase expressed specifically in B and T cells that modulates the threshold required for activation/costimulation (32), and Ca 2+ /calmodulin-dependent protein kinase IV, a key kinase likely involved in signal transduction events downstream of Txk (33).
Some of the changes in gene expression during AIDS may also contribute to CD4 + T cell depletion and limit reconstitution through the microenvironment-impairing deposition of collagen (8), such as increased expression of the gene encoding a cell surface proteoglycan, syndecan-1, which colocalizes with fibrosis-promoting-TGF-β in fibrotic and inflamed areas of cirrhotic human liver (34).
We interpret the small number of genes with altered expression common to all stages as evidence that there is a key set of genes required by the host to partially contain the virus. Many of the altered genes that are common to all stages of infection are related to immune activation and immune defenses, most prominently, CD38, a known marker for immune activation and poor prognosis when highly expressed in HIV-1 infection (35, 36), and genes encoding products associated with NK cells, IFNs, CD8 + T cell-mediated cytotoxicity, and antiviral chemokines. Altered expression of these genes highlights the importance of innate immunity and the IFN system throughout HIV-1 infection.
Our microarray study revealed very little overlap (<5%) with recent small interfering RNAknockdown screens (37-39) designed to identify important host factors required for HIV-1 infection. This is likely due to differences between in vitro systems utilizing laboratoryadapted strains of virus and cell lines vs biopsied lymph nodes from HIV-1-infected individuals. Moreover, microarray assays measure change at the mRNA level and would thus not detect posttranscriptional changes in gene expression.
This microarray study is a descriptive approach to glean key insights into systems biology. The genes we identified in stage-specific, transcriptional signatures are a good starting point for further investigations of their roles in HIV-1 pathogenesis using in situ technologies to identify the types of cells in which gene expression has been altered and immunohistochemistry to identify potential changes in protein expression. In addition, it will be fruitful to examine the relationships between gene expression and infected cells, CD4 + T cell depletion, and collagen deposition, one pathological consequence of infection. Ultimately, these studies may be used not only to better understand viral pathogenesis during the various stages of HIV-1 disease but also to identify adjunctive approaches to improving treatment and immune reconstitution. Classification of altered genes in LT from HIV-1-infected patients into disease stages and representative hierarchical clustering reveals stage-specific gene signatures. Genes with altered expression (≥1.7 times the level at uninfected baseline, p < 0.05) at the three stages of HIV-1 infection were characterized as the following: unique to the acute stage (S1), asymptomatic stage (S2), or AIDS stage (S3); C1, common to all stages; C2, common to acute and asymptomatic stages; C3, common to asymptomatic and AIDS stages; and C4, common to acute and AIDS stages. A, Hierarchical cluster analysis of altered genes from HIV-1-infected subjects (stage indicated at the bottom). Green, red, and black areas indicate, respectively, decreased, increased, and no significant change in expression compared with uninfected controls. B, Venn diagram depicting the number of genes with altered expression.
FIGURE 2.
In human LT of HIV-1-infected subjects, the general functional categories of genes with altered expression (≥1.7 times the level at baseline, p < 0.05). A, Common to all stages (C1); B, unique to the acute stage (S1); C, unique to the asymptomatic stage (S2); and D, unique to the AIDS stage (S3). Green and red letters indicate, respectively, decreased and increased expression. The size of each sector in a pie diagram is proportional to the number of genes in its category (in parentheses). All genes and their names derived from abbreviations can be found in supplemental Table I . Illustration of altered genes in the acute stage related to canonical apoptotic signaling pathways reveals activation of the Fas-Fas ligand pathway. Ingenuity Pathways Analysis software was used to identify altered genes related to canonical apoptotic pathways; red indicates genes significantly increased in expression and black indicates no significant change in gene expression. Male  32  Caucasian  400  15,284   1431  Asympt  Male  34  Caucasian  333  71,200   1464  Asympt  Male  34  Caucasian  202  122,000   1456  Asympt  Male  49  Caucasian  478  174,000   1408  Asympt  Male  39  Caucasian  685  20,014   1436  Asympt  Male  63  Caucasian  248  46,400   1407  Asympt  Male  35  Caucasian  372  31,922   1459  Asympt  Male  36  Caucasian  286  >100,000   1438  AIDS  Male  49  Caucasian  147  4,960   1406  AIDS  Male  45  African American  188  10,684   1462  AIDS  Male  43  Caucasian  81  35,000   1327  AIDS  Female  40  African American  112  12,046 Note. Undetectable, assay limit of detection (50 copies/ml). 
